Table SI. Clinicopathological data of the cohort.

Characteristic	Number of patients (%)
Age, years	
<60	82 (35.8)
≥60	147 (64.1)
Sex	
Male	165 (72.0)
Female	64 (27.9)
Ethnicity	
Han	119 (51.9)
Kazakh	110 (48.0)
Tumor size, cm	
≥3	157 (58.5)
<3	72 (31.4)
Tumor location	
Upper	12 (5.2)
Middle	139 (60.6)
Lower	78 (34.0)
Lymph node metastasis	
No	155 (67.6)
Yes	74 (32.3)
Degree of differentiation	
Poorly differentiated	46 (20.0)
Moderately differentiated	123 (53.7)
Well differentiated	60 (26.2)
Vascular invasion	
No	187 (81.6)
Yes	42 (18.3)
Nerve invasion	
No	181 (79.0)
Yes	48 (20.9)
Hematogenous metastasis	
No	189 (86.4)
Yes	31 (13.5)
Post-radiochemotherapy	
No	150 (65.5)
Yes	79 (34.4)
MTA1	
Positive	194 (84.7)
Negative	35 (15.2)
SOX4	
Positive	153 (66.8)
Negative	76 (33.1)
EZH2	
Positive	95 (41.4)
Negative	134 (58.5)
AJCC stage	
IA+B	18 (7.8)
IIA+B	143 (62.4)
IIIA+B	47 (20.5)
IVA+B	21 (9.1)

AJCC, American Joint Committee on Cancer; EZH2, enhancer of zeste homolog 2; MTA1, metastasis-associated protein 1.